Rapt Therapeutics Inc.
GSK Enters Agreement to Acquire RAPT Therapeutics for $2.2 Billion
Summary
RAPT Therapeutics, Inc. announced on January 19, 2026, that it has entered into an Agreement and Plan of Merger with GlaxoSmithKline LLC, a wholly-owned subsidiary of GSK plc, to be acquired for $58.00 per share in cash, representing an aggregate equity value of $2.2 billion. GSK will also be responsible for milestone and royalty payments related to RAPT Therapeutics' drug ozureprubart. The acquisition is expected to close in the first quarter of 2026, pending regulatory approvals and the tender of a majority of RAPT's shares.
Profitelligence Alerts
Get alerts for RAPT
Be first to know when Rapt Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Rapt Therapeutics Inc.
Rapt Therapeutics Inc. is a biotechnology firm focused on the discovery, development, and commercialization of oral small molecule therapies for oncology and inflammatory diseases. Its primary mission is to create novel treatments by harnessing its proprietary drug discovery platform, which targets key pathways responsible for the progression of these complex conditions. Rapt Therapeutics is notably advancing its development of selective inhibitors for immune checkpoint inhibitors within the broader cancer treatment landscape, potentially enhancing the efficacy of existing therapies. The company's pipeline includes multiple drug candidates tailored for specific types of cancer and chronic inflammatory disorders, underscoring its commitment to addressing unmet medical needs. By concentrating efforts on innovative approaches that modulate immune and inflammatory responses, Rapt Therapeutics plays a significant role in shaping the future of precision medicine in the biopharmaceutical industry. Founded in 2015 and leveraging advanced scientific insights, Rapt Therapeutics represents an important component of the biotech sector's efforts to push boundaries in disease treatment and improve patient outcomes.
Official SEC Documents
Advertisement